Literature DB >> 218452

Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective.

J F Caro, A Besarab, J T Flynn.   

Abstract

Prostaglandin E concentrations were measured in a patiet with breast carcinoma, hypercalcemia, undetectable parathyroid hormone (PTH) and no evidence of bone metastases. Catheterization of the drainage bed of her tumor documented production of E series prostaglandins. Treatment with the largest recommended doses of indomethacin for 10 days failed to lower her plasma prostaglandin E (PGE) concentrations or to correct the hypercalcemia, but it normalized urinary excretion of PGE. Subsequent chemotherapy reduced prostaglandin concentrations toward normal values concomitant with a reduction of clinically estimated tumor burden. During this period of time, serum calcium concentrations had no consistent relationship to the plasma PGE levels. We suggest that PGE merely reflected the tumor burden of this patient and did not directly contribute to the genesis of her hypercalcemia. The pertinent literature relating PGE and hypercalcemia is reviewed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218452     DOI: 10.1016/0002-9343(79)90561-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.

Authors:  H A Kulenkampff; T Dreyer; W Kersjes; G Delling
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

3.  Fatigue, weakness, anemia and hypercalcemia in a 63-year-old woman.

Authors:  A Gelston; H Sheldon
Journal:  Can Med Assoc J       Date:  1981-02-15       Impact factor: 8.262

4.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

5.  Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients.

Authors:  T Malachi; C Chaimoff; N Feller; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

6.  Prostaglandin E2 and cyclic nucleotides in plasma and urine of colonic cancer patients.

Authors:  C Chaimoff; T Malachi; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia.

Authors:  S H Doppelt; D M Slovik; R M Neer; J Nolan; R M Zusman; J T Potts
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

8.  Prostaglandin E production and hypercalcaemia in rats bearing the Walker carcinosarcoma.

Authors:  H W Seyberth; G Bonsch; H Müller; H W Minne; T Erlenmaier; K Strein; H Imbeck; R Mrongovius
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.